A scientific conclave in Haridwar focused on the Indian Pharmacopoeia (IP) 2026 to enhance awareness of new provisions and ensure quality compliance in the pharmaceutical manufacturing sector. Organized by the Indian Pharmacopoeia Commission (IPC) in collaboration with the Association of Devbhumi Pharma Industries and Uttarakhand pharmaceutical associations, the event gathered industry professionals to address recent standards and their implementation.
Uttarakhand, a key pharmaceutical manufacturing hub in India, has effectively utilized the IP and Indian Pharmacopoeia Reference Substances to uphold medicine quality. The conclave aimed to bolster industry awareness, facilitate compliance with pharmacopoeial requirements, and encourage uniform adoption of IP standards, offering support to pharmaceutical stakeholders in the state.
Dr. V Kalaiselvan, Secretary-cum-Scientific Director at IPC, emphasized the IP’s role in setting validated quality standards for medicines, contributing to India’s global pharmaceutical prominence. He highlighted the advancements in IP 2026 and urged industry involvement in ensuring the standards’ effective implementation.
Technical discussions at the conclave covered various IP aspects, such as recent standards, reference substances, quality management systems, and analytical investigations. Participants gained practical insights into applying IP standards in pharmaceutical manufacturing and quality control, fostering industry knowledge and compliance.
The event concluded with networking opportunities, facilitating ongoing discussions among regulators, industry representatives, and experts to advance pharmaceutical quality and compliance in Uttarakhand and nationwide.
